BRAF and medical procedure: The Food and Drug Administration (FDA) recently approved combined BRAF/MEK inhibition with dabrafenib and trametinib for the treatment of patients with advanced solid tumors harboring BRAF V600E mutations, based on the outcomes of basket trials enrolling patients with 24 tumor types (including 2 patients with MiNEN and 2 patients with colon NEC) [116].